{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.0","upperLimit":"37.7","value":"33.3"},{"groupId":"OG001","lowerLimit":"38.6","upperLimit":"47.9","value":"43.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"447"},{"groupId":"OG001","value":"444"}],"units":"Participants"}],"description":"Grade 3 or higher Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 radiation mucositis definitely, probably, or possibly related to protocol treatment. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin","id":"OG000","title":"RT + Cisplatin"},{"description":"Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin plus cetuximab","id":"OG001","title":"RT + Cisplatin + Cetuximab"}],"paramType":"NUMBER","populationDescription":"Randomized eligible patients with follow-up data","reportingStatus":"POSTED","timeFrame":"From start of treatment until 434 failures have occurred, approximately 5 years from start of study. (Patients are followed until death or study termination, whichever occurs first.)","title":"Rate of Mucositis Toxicity ≥ Grade 3","type":"SECONDARY","unitOfMeasure":"percentage of participants"}